Rilmenidine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Rilmenidine
Accession Number
DB11738
Type
Small Molecule
Groups
Approved, Investigational
Description

Rilmenidine has been used in trials studying the treatment of Hypertension and Chronic Kidney Disease.

Structure
Thumb
Synonyms
  • HYPERIUM
Product Ingredients
IngredientUNIICASInChI Key
Rilmenidine Phosphate59QD64Q32M85409-38-7ZJCOWRFWZOAVFY-UHFFFAOYSA-N
Categories
UNII
P67IM25ID8
CAS number
54187-04-1
Weight
Average: 180.251
Monoisotopic: 180.126263143
Chemical Formula
C10H16N2O
InChI Key
CQXADFVORZEARL-UHFFFAOYSA-N
InChI
InChI=1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12)
IUPAC Name
N-(dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine
SMILES
C1CC1C(NC1=NCCO1)C1CC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UAlpha-2A adrenergic receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Rilmenidine.Experimental
AcebutololRilmenidine may increase the hypotensive activities of Acebutolol.Approved, Investigational
AcemetacinThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineAcepromazine may decrease the vasoconstricting activities of Rilmenidine.Approved, Vet Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Rilmenidine.Approved, Investigational
AliskirenRilmenidine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololRilmenidine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanRilmenidine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineRilmenidine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmitriptylineAmitriptyline may decrease the vasoconstricting activities of Rilmenidine.Approved
AmlodipineRilmenidine may increase the hypotensive activities of Amlodipine.Approved
AmoxapineAmoxapine may decrease the vasoconstricting activities of Rilmenidine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Rilmenidine.Approved, Illicit, Investigational
AripiprazoleAripiprazole may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
AsenapineAsenapine may decrease the vasoconstricting activities of Rilmenidine.Approved
AtenololRilmenidine may increase the hypotensive activities of Atenolol.Approved
AvanafilAvanafil may increase the antihypertensive activities of Rilmenidine.Approved
BarnidipineRilmenidine may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilRilmenidine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideRilmenidine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Rilmenidine.Withdrawn
Benzylpenicilloyl PolylysineRilmenidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilRilmenidine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololRilmenidine may increase the hypotensive activities of Betaxolol.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Rilmenidine.Approved
BevantololBevantolol may decrease the vasoconstricting activities of Rilmenidine.Approved
BietaserpineRilmenidine may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostRilmenidine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololRilmenidine may increase the hypotensive activities of Bisoprolol.Approved
BosentanBosentan may increase the hypotensive activities of Rilmenidine.Approved, Investigational
BQ-123Rilmenidine may increase the hypotensive activities of BQ-123.Investigational
BretyliumRilmenidine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleBrexpiprazole may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Rilmenidine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Rilmenidine.Experimental
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Rilmenidine.Approved, Investigational
BucindololBucindolol may decrease the vasoconstricting activities of Rilmenidine.Investigational
BunazosinBunazosin may decrease the vasoconstricting activities of Rilmenidine.Investigational
BupranololRilmenidine may increase the hypotensive activities of Bupranolol.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Rilmenidine.Approved
CadralazineRilmenidine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineRilmenidine may increase the hypotensive activities of Cafedrine.Investigational
CandesartanRilmenidine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilRilmenidine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilRilmenidine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilRilmenidine may increase the hypotensive activities of Captopril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Rilmenidine.Withdrawn
CarteololRilmenidine may increase the hypotensive activities of Carteolol.Approved
CarvedilolRilmenidine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololRilmenidine may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideRilmenidine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineChlorpromazine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational, Vet Approved
ChlorthalidoneRilmenidine may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineRilmenidine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilRilmenidine may increase the hypotensive activities of Cilazapril.Approved
ClonidineClonidine may increase the hypotensive activities of Rilmenidine.Approved
CloranololRilmenidine may increase the hypotensive activities of Cloranolol.Experimental
ClozapineClozapine may decrease the vasoconstricting activities of Rilmenidine.Approved
CryptenamineRilmenidine may increase the hypotensive activities of Cryptenamine.Approved
CyclopenthiazideRilmenidine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideRilmenidine may increase the hypotensive activities of Cyclothiazide.Approved
DapiprazoleDapiprazole may decrease the vasoconstricting activities of Rilmenidine.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Rilmenidine.Approved, Investigational
DelaprilRilmenidine may increase the hypotensive activities of Delapril.Investigational
DeserpidineRilmenidine may increase the hypotensive activities of Deserpidine.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Rilmenidine.Approved, Investigational
DextroamphetamineDextroamphetamine may decrease the vasoconstricting activities of Rilmenidine.Approved, Illicit
DiazoxideDiazoxide may increase the hypotensive activities of Rilmenidine.Approved
DiethylnorspermineRilmenidine may increase the hypotensive activities of Diethylnorspermine.Investigational
DihydralazineRilmenidine may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Rilmenidine.Approved, Investigational
DiltiazemRilmenidine may increase the hypotensive activities of Diltiazem.Approved, Investigational
DipyridamoleDipyridamole may increase the antihypertensive activities of Rilmenidine.Approved
DorzolamideRilmenidine may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Rilmenidine.Approved
DoxepinDoxepin may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
DronedaroneDronedarone may decrease the vasoconstricting activities of Rilmenidine.Approved
DroperidolDroperidol may decrease the vasoconstricting activities of Rilmenidine.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Rilmenidine.Approved
EfonidipineRilmenidine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilRilmenidine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatRilmenidine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineRilmenidine may increase the hypotensive activities of Endralazine.Experimental
EpanololRilmenidine may increase the hypotensive activities of Epanolol.Experimental
EpinephrineEpinephrine may decrease the vasoconstricting activities of Rilmenidine.Approved, Vet Approved
EpoprostenolRilmenidine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanRilmenidine may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Rilmenidine.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Rilmenidine.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Rilmenidine.Approved
EscitalopramEscitalopram may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
FelodipineRilmenidine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenoldopamRilmenidine may increase the hypotensive activities of Fenoldopam.Approved
Ferulic acidRilmenidine may increase the hypotensive activities of Ferulic acid.Experimental
FlupentixolFlupentixol may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational, Withdrawn
FosinoprilRilmenidine may increase the hypotensive activities of Fosinopril.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Rilmenidine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Rilmenidine.Approved, Investigational, Vet Approved
GuanabenzRilmenidine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelRilmenidine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineRilmenidine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineRilmenidine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Rilmenidine.Approved, Investigational
GuanoclorRilmenidine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzRilmenidine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanRilmenidine may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Rilmenidine.Experimental
HexamethoniumRilmenidine may increase the hypotensive activities of Hexamethonium.Experimental
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Rilmenidine.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Rilmenidine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Rilmenidine.Approved
HydrochlorothiazideRilmenidine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideRilmenidine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IloperidoneIloperidone may decrease the vasoconstricting activities of Rilmenidine.Approved
IloprostIloprost may increase the hypotensive activities of Rilmenidine.Approved, Investigational
ImidaprilRilmenidine may increase the hypotensive activities of Imidapril.Investigational
ImipramineImipramine may decrease the vasoconstricting activities of Rilmenidine.Approved
IndapamideRilmenidine may increase the hypotensive activities of Indapamide.Approved
IndenololRilmenidine may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Rilmenidine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Rilmenidine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Rilmenidine.Withdrawn
IrbesartanRilmenidine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Rilmenidine.Approved
IsradipineRilmenidine may increase the hypotensive activities of Isradipine.Approved, Investigational
KetanserinRilmenidine may increase the hypotensive activities of Ketanserin.Investigational
LabetalolRilmenidine may increase the hypotensive activities of Labetalol.Approved
LacidipineRilmenidine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostRilmenidine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineRilmenidine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Rilmenidine.Approved, Investigational
LinsidomineRilmenidine may increase the hypotensive activities of Linsidomine.Experimental
LisdexamfetamineLisdexamfetamine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
LisinoprilRilmenidine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LofexidineRilmenidine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanRilmenidine may increase the hypotensive activities of Losartan.Approved
MacitentanRilmenidine may increase the hypotensive activities of Macitentan.Approved
ManidipineRilmenidine may increase the hypotensive activities of Manidipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Rilmenidine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Rilmenidine.Approved, Investigational
MethoserpidineRilmenidine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineMethotrimeprazine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
MethyldopaRilmenidine may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Rilmenidine.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Rilmenidine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Rilmenidine.Approved, Investigational
MetipranololRilmenidine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneRilmenidine may increase the hypotensive activities of Metolazone.Approved
MetoprololRilmenidine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineRilmenidine may increase the hypotensive activities of Metyrosine.Approved
MibefradilRilmenidine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MilnacipranMilnacipran may increase the tachycardic activities of Rilmenidine.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Rilmenidine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Rilmenidine.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Rilmenidine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Rilmenidine.Approved, Investigational
MoexiprilRilmenidine may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Rilmenidine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Rilmenidine.Approved, Investigational
MuzolimineRilmenidine may increase the hypotensive activities of Muzolimine.Experimental
NadololRilmenidine may increase the hypotensive activities of Nadolol.Approved
NaftopidilRilmenidine may increase the hypotensive activities of Naftopidil.Investigational
NebivololRilmenidine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may decrease the vasoconstricting activities of Rilmenidine.Approved, Withdrawn
NialamideNialamide may increase the hypotensive activities of Rilmenidine.Withdrawn
NicardipineRilmenidine may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicergolineNicergoline may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
NicorandilRilmenidine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineRilmenidine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineRilmenidine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineRilmenidine may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineRilmenidine may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineRilmenidine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Rilmenidine.Approved, Investigational
NortriptylineNortriptyline may decrease the vasoconstricting activities of Rilmenidine.Approved
ObinutuzumabRilmenidine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Rilmenidine.Withdrawn
OlanzapineOlanzapine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
OlmesartanRilmenidine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OmapatrilatRilmenidine may increase the hypotensive activities of Omapatrilat.Investigational
OxprenololRilmenidine may increase the hypotensive activities of Oxprenolol.Approved
PaliperidonePaliperidone may decrease the vasoconstricting activities of Rilmenidine.Approved
PargylinePargyline may increase the hypotensive activities of Rilmenidine.Approved
PenbutololRilmenidine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentoliniumRilmenidine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Rilmenidine.Approved, Investigational
PerindoprilRilmenidine may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Rilmenidine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Rilmenidine.Withdrawn
PhenoxybenzamineRilmenidine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Rilmenidine.Withdrawn
PhentolamineRilmenidine may increase the hypotensive activities of Phentolamine.Approved
PinacidilPinacidil may increase the hypotensive activities of Rilmenidine.Approved
PindololRilmenidine may increase the hypotensive activities of Pindolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Rilmenidine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Rilmenidine.Withdrawn
PizotifenPizotifen may decrease the vasoconstricting activities of Rilmenidine.Approved
Platelet Activating FactorRilmenidine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideRilmenidine may increase the hypotensive activities of Polythiazide.Approved
PrazosinPrazosin may increase the hypotensive activities of Rilmenidine.Approved
ProcaineProcaine may increase the hypotensive activities of Rilmenidine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Rilmenidine.Approved, Investigational
PromazinePromazine may decrease the vasoconstricting activities of Rilmenidine.Approved, Vet Approved
PropericiazinePropericiazine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
PropiomazinePropiomazine may decrease the vasoconstricting activities of Rilmenidine.Approved
PropiverinePropiverine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
PropranololRilmenidine may increase the hypotensive activities of Propranolol.Approved, Investigational
QuetiapineQuetiapine may decrease the vasoconstricting activities of Rilmenidine.Approved
QuinaprilRilmenidine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineQuinidine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Rilmenidine.Approved
RacepinephrineRacepinephrine may decrease the vasoconstricting activities of Rilmenidine.Approved
RamiprilRilmenidine may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Rilmenidine.Approved
RemikirenRilmenidine may increase the hypotensive activities of Remikiren.Approved
RescinnamineRilmenidine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RiociguatRilmenidine may increase the hypotensive activities of Riociguat.Approved
RisperidoneRisperidone may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RituximabRilmenidine may increase the hypotensive activities of Rituximab.Approved
SafrazineSafrazine may increase the hypotensive activities of Rilmenidine.Withdrawn
SaprisartanRilmenidine may increase the hypotensive activities of Saprisartan.Experimental
SelegilineSelegiline may increase the hypotensive activities of Rilmenidine.Approved, Investigational, Vet Approved
SelexipagRilmenidine may increase the hypotensive activities of Selexipag.Approved
SildenafilSildenafil may increase the antihypertensive activities of Rilmenidine.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Rilmenidine.Approved
SitaxentanRilmenidine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilRilmenidine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Rilmenidine.Approved
TadalafilTadalafil may increase the antihypertensive activities of Rilmenidine.Approved, Investigational
TalinololRilmenidine may increase the hypotensive activities of Talinolol.Investigational
TamsulosinTamsulosin may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
TelmisartanRilmenidine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilRilmenidine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinTerazosin may decrease the vasoconstricting activities of Rilmenidine.Approved
TerlipressinRilmenidine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineRilmenidine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineRilmenidine may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the antihypertensive activities of Rilmenidine.Approved
ThioproperazineThioproperazine may decrease the vasoconstricting activities of Rilmenidine.Approved
ThioridazineThioridazine may decrease the vasoconstricting activities of Rilmenidine.Approved, Withdrawn
TiboloneRilmenidine may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenRilmenidine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololRilmenidine may increase the hypotensive activities of Timolol.Approved
TolazolineRilmenidine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolonidineRilmenidine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Rilmenidine.Approved
TorasemideRilmenidine may increase the hypotensive activities of Torasemide.Approved
TrandolaprilRilmenidine may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Rilmenidine.Approved, Investigational
TravoprostRilmenidine may increase the hypotensive activities of Travoprost.Approved
TrazodoneTrazodone may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
TreprostinilRilmenidine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideRilmenidine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
TrimazosinTrimazosin may increase the hypotensive activities of Rilmenidine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Rilmenidine.Approved, Investigational
TrimipramineTrimipramine may decrease the vasoconstricting activities of Rilmenidine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Rilmenidine.Approved, Investigational
UnoprostoneRilmenidine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may decrease the vasoconstricting activities of Rilmenidine.Investigational
ValsartanRilmenidine may increase the hypotensive activities of Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Rilmenidine.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Rilmenidine.Approved
VerapamilVerapamil may decrease the vasoconstricting activities of Rilmenidine.Approved
VincamineRilmenidine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineRilmenidine may increase the hypotensive activities of Vinpocetine.Investigational
XipamideRilmenidine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineRilmenidine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Rilmenidine.Approved, Investigational, Vet Approved
ZiprasidoneZiprasidone may decrease the vasoconstricting activities of Rilmenidine.Approved
ZofenoprilRilmenidine may increase the hypotensive activities of Zofenopril.Experimental
ZuclopenthixolZuclopenthixol may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C11120
PubChem Compound
68712
PubChem Substance
347828096
ChemSpider
61963
BindingDB
50070328
ChEBI
8862
ChEMBL
CHEMBL289480
Wikipedia
Rilmenidine
ATC Codes
C02AC06 — Rilmenidine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4WithdrawnTreatmentChronic Kidney Disease (CKD) / High Blood Pressure (Hypertension)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.34 mg/mLALOGPS
logP1.43ALOGPS
logP1.58ChemAxon
logS-2.1ALOGPS
pKa (Strongest Basic)7.11ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area33.62 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity49.79 m3·mol-1ChemAxon
Polarizability20.38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as oxazolines. These are organic compounds containing 1,3-oxazoline, a five-membered ring with a nitrogen and an oxygen atoms at the 1- and 3-position, respectively. Additionally, it contains two double bonds.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azolines
Sub Class
Oxazolines
Direct Parent
Oxazolines
Alternative Parents
Isoureas / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Hydrocarbon derivatives
Substituents
Oxazoline / Isourea / Oxacycle / Azacycle / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carboximidamide / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
isourea (CHEBI:8862)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP, Eglen RM, Blue DR Jr: Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol. 1999 Mar;126(6):1522-30. [PubMed:10217548]

Drug created on October 20, 2016 14:43 / Updated on August 02, 2018 06:28